Similarly, the American Diabetes Association and the European Association for the Study of Diabetes advise using SGLT2 inhibitors in patients with diabetes who also have co-morbid conditions such as cardiovascular disease and chronic kidney disease [20,22]. Here, SLC5A2 is linked to diabetes mellitus.